Genentech 401(k) Investor Wants to Take Partial Loss to 9th Cir.

A participant in the $7.6 billion 401(k) plan of California-based biotechnology company Genentech Inc. want to go directly to the Ninth Circuit with claims challenging the performance of the plan’s custom target date funds, a federal court motion shows.

Matthew Wehner wants the June decision dismissing his challenge to Genentech’s target date funds certified as a final judgment that can be appealed directly to the U.S. Court of Appeals for the Ninth Circuit. Wehner’s Sept. 24 motion, filed in the U.S. District Court for the Northern District of California, also seeks a pause on the rest of his lawsuit to ...